Trevena, Inc (TRVN) Fair Value & Analysis
Healthcare · US · Market cap $9.5K
Trevena, Inc
TRVN · US
Fair value as of: Jun 26, 2026
From 3 valuation models · updated 7 days ago
Fair value updated Jun 26, 2026 — revised from $0.9300 to $0.0020 (−99.8%) since Jun 24, 2026. Share price +100.0% over the past month.
Price vs Fair Value (12 months)
12‑month range $0.0010 – $1.10 · fair‑value band $0.0020 – $0.0020 · the $0.0020 price screens below the $0.0020 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Trevena, Inc (TRVN) currently trades at $0.0020, while our model-based Fair Value estimate is $0.0020 — implying the stock looks roughly 0.2% undervalued today. We read business quality at 29/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Trailing-twelve-month revenue stands at $546K. Revenue grew 57.2% year over year. Net debt stands at $3.3M. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
Revenue & earnings trend
FY2019 – FY2023 · reported fiscal years
Trevena, Inc reported revenue of $3.1M in FY2023 versus $31.0K in FY2019, a compound +216.9%/yr. Reported net income was −$40.3M in FY2023.
Is TRVN fairly valued? → Check now
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$582.92 | R$95.50 | -84% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €247.60 | €180.06 | -27% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $286.41 | $106.81 | -63% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,011,109 KRW | +1% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Trevena, Inc (TRVN) undervalued?
What is the fair value of TRVN?
What is the quality score of TRVN?
What is the revenue of Trevena, Inc (TRVN)?
What is the net profit margin of TRVN?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.